Evidence map›Paper›PMID 29670626›Full record

ArticleFrontiers in immunology2018

Prophylactic and Therapeutic Effects of Interleukin-2 (IL-2)/Anti-IL-2 Complexes in Systemic Lupus Erythematosus-Like Chronic Graft-Versus-Host Disease.

Stefan Heiler, Jonas Lötscher, Matthias Kreuzaler, Johanna Rolink, Antonius Rolink

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Regulatory T Cells in Systemic Sclerosis.Frontiers in immunology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Stefan HeilerDevelopmental and Molecular Immunology, Department of Biomedicine, University of Basel, Basel, Switzerland.
Jonas LötscherDevelopmental and Molecular Immunology, Department of Biomedicine, University of Basel, Basel, Switzerland.
Matthias KreuzalerDevelopmental and Molecular Immunology, Department of Biomedicine, University of Basel, Basel, Switzerland.
Johanna RolinkDevelopmental and Molecular Immunology, Department of Biomedicine, University of Basel, Basel, Switzerland.
Antonius RolinkDevelopmental and Molecular Immunology, Department of Biomedicine, University of Basel, Basel, Switzerland.
University of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Murine chronic graft-versus-host-disease (cGvHD) induced by injection of parental lymphocytes into F1 hybrids results in a disease similar to systemic lupus erythematosus. Here, we have used DBA/2 T cell injection into (C57BL/6 × DBA/2)F1 (BDF1) mice as a model system to test the prophylactic and therapeutic effects of interleukin-2 (IL-2)/anti-IL-2 immune complexes on the course of cGvHD. Our findings demonstrate that pretreatment with Treg inducing JES6/IL-2 complexes render BDF1 mice largely resistant to induction of cGvHD, whereas pretreatment with CD8

Indexed as

AnimalsAntibodiesAntigen-Antibody ComplexCD8-Positive T-LymphocytesCells, CulturedDisease Models, AnimalGraft vs Host DiseaseHumansImmunotherapyInterleukin-2Lupus Erythematosus, SystemicLymphocyte TransfusionMiceMice, Inbred C57BLMice, Inbred DBAT-Lymphocytes, RegulatoryAntibodiesAntigen-Antibody ComplexInterleukin-2autoantibodieschronic graft-versus-host-diseasedonor CD8+ T cellshost regulatory T cellsimmune complex-mediated glomerulonephritisinterleukin-2/anti-interleukin-2 complexesinterleukin-2 receptorlupus

Identifiers

PMID29670626
PMCPMC5893767
OpenAlexW2795595031

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.